{
  "ticker": "MOH",
  "entities": [
    {
      "text": "Molina Healthcare, Inc",
      "label": "ORG",
      "start": 0,
      "end": 22,
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "context": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure follow",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "MOH",
      "label": "ORG",
      "start": 29,
      "end": 32,
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "context": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a stri",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "52-week",
      "label": "DATE",
      "start": 155,
      "end": 162,
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "context": "nd sector headwinds, pushing the stock toward its 52-week low. Investors are weighing mixed signals as pric",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Mizuho",
      "label": "ORG",
      "start": 279,
      "end": 285,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "and earnings forecasts shift.\nPositive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "MOH",
      "label": "ORG",
      "start": 314,
      "end": 317,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "ive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform”",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "400",
      "label": "MONEY",
      "start": 324,
      "end": 327,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "ent:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, im",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "330",
      "label": "MONEY",
      "start": 332,
      "end": 335,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "uho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying r",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "roughly 49%",
      "label": "PERCENT",
      "start": 384,
      "end": 395,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "0 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price tar",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Mizuho",
      "label": "ORG",
      "start": 424,
      "end": 430,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan tr",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "JP Morgan",
      "label": "ORG",
      "start": 468,
      "end": 477,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "vels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but le",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "333",
      "label": "MONEY",
      "start": 507,
      "end": 510,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecti",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "350",
      "label": "MONEY",
      "start": 517,
      "end": 520,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "JP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautiou",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "MOH",
      "label": "ORG",
      "start": 530,
      "end": 533,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "immed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook wit",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "JP Morgan",
      "label": "ORG",
      "start": 610,
      "end": 619,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "ng cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Health",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Molina Healthcare",
      "label": "ORG",
      "start": 656,
      "end": 673,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "ss.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2 2025",
      "label": "DATE",
      "start": 695,
      "end": 702,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidan",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "full-year",
      "label": "DATE",
      "start": 732,
      "end": 741,
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "context": "preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 810,
      "end": 812,
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "context": "details to be confirmed in the official release.\nQ2 preliminary results\nNeutral Sentiment:\nAround Jul",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "July 11",
      "label": "DATE",
      "start": 859,
      "end": 866,
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "context": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 ea",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FY2025",
      "label": "DATE",
      "start": 907,
      "end": 913,
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "context": "d July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertai",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "MOH",
      "label": "ORG",
      "start": 937,
      "end": 940,
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "context": "ublished a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-car",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Medicaid",
      "label": "ORG",
      "start": 970,
      "end": 978,
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "context": "gs forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.\nFY2025 earnings predictions",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FY2025",
      "label": "DATE",
      "start": 1001,
      "end": 1007,
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "context": "ing uncertainty in Medicaid managed-care margins.\nFY2025 earnings predictions\nNegative Sentiment:\nCantor F",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Cantor Fitzgerald",
      "label": "ORG",
      "start": 1049,
      "end": 1066,
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "context": ".\nFY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 fro",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FY2025",
      "label": "DATE",
      "start": 1075,
      "end": 1081,
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "context": "ons\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "MOH",
      "label": "ORG",
      "start": 1099,
      "end": 1102,
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "context": "Cantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "22.00",
      "label": "MONEY",
      "start": 1107,
      "end": 1112,
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "context": "itzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, refle",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "24.65",
      "label": "MONEY",
      "start": 1119,
      "end": 1124,
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "context": "t its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concer",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "24.40",
      "label": "MONEY",
      "start": 1150,
      "end": 1155,
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "context": "OH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.\nCantor F",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Cantor Fitzgerald",
      "label": "ORG",
      "start": 1197,
      "end": 1214,
      "sentence": "Cantor Fitzgerald cuts EPS\nNegative Sentiment:",
      "context": "f $24.40, reflecting concerns over profitability.\nCantor Fitzgerald cuts EPS\nNegative Sentiment:\nMorgan Stanley downg",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Morgan Stanley",
      "label": "ORG",
      "start": 1244,
      "end": 1258,
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "context": "y.\nCantor Fitzgerald cuts EPS\nNegative Sentiment:\nMorgan Stanley downgraded MOH from “Overweight” to “Equal Weight",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "MOH",
      "label": "ORG",
      "start": 1270,
      "end": 1273,
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "context": "EPS\nNegative Sentiment:\nMorgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed i",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "266",
      "label": "MONEY",
      "start": 1337,
      "end": 1340,
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "context": "ght” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "364",
      "label": "MONEY",
      "start": 1347,
      "end": 1350,
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "context": "qual Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nM",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Morgan Stanley",
      "label": "ORG",
      "start": 1399,
      "end": 1413,
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "context": "4, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:\nMOH stock sank to a",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "MOH",
      "label": "ORG",
      "start": 1444,
      "end": 1447,
      "sentence": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "context": "ide.\nMorgan Stanley downgrade\nNegative Sentiment:\nMOH stock sank to a 52-week low amid the earnings est",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "52-week",
      "label": "DATE",
      "start": 1464,
      "end": 1471,
      "sentence": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "context": "downgrade\nNegative Sentiment:\nMOH stock sank to a 52-week low amid the earnings estimate revisions and broa",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "52-week",
      "label": "DATE",
      "start": 1580,
      "end": 1587,
      "sentence": "Stock hits 52-week low\nNegative Sentiment:",
      "context": "r pressures on managed care providers.\nStock hits 52-week low\nNegative Sentiment:\nAnalysts warn MOH faces n",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "MOH",
      "label": "ORG",
      "start": 1626,
      "end": 1629,
      "sentence": "Analysts warn MOH faces near-term challenges in its Medicaid plans and may face further downgrades absent clearer margin improvements.",
      "context": "its 52-week low\nNegative Sentiment:\nAnalysts warn MOH faces near-term challenges in its Medicaid plans",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Medicaid",
      "label": "ORG",
      "start": 1664,
      "end": 1672,
      "sentence": "Analysts warn MOH faces near-term challenges in its Medicaid plans and may face further downgrades absent clearer margin improvements.",
      "context": "alysts warn MOH faces near-term challenges in its Medicaid plans and may face further downgrades absent clea",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1+ days ago",
      "label": "DATE",
      "start": 1781,
      "end": 1792,
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "context": "n improvements.\nAnalyst warns of downgrade\nPosted 1+ days ago\nAI Generated. May Contain Errors.",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AI Generated",
      "label": "ORG",
      "start": 1793,
      "end": 1805,
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "context": "ts.\nAnalyst warns of downgrade\nPosted 1+ days ago\nAI Generated. May Contain Errors.",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    }
  ],
  "relationships": [
    {
      "type": "SVO",
      "subject": "Investors",
      "verb": "weighing",
      "object": "signals",
      "sentence": "Investors are weighing mixed signals as price targets adjust and earnings forecasts shift.",
      "importance": 1
    },
    {
      "type": "SVO",
      "subject": "Mizuho",
      "verb": "lowered",
      "object": "target",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "importance": 33
    },
    {
      "type": "SVO",
      "subject": "Mizuho",
      "verb": "cuts",
      "object": "target",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "importance": 33
    },
    {
      "type": "SVO",
      "subject": "Morgan",
      "verb": "trimmed",
      "object": "target",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "importance": 33
    },
    {
      "type": "SVO",
      "subject": "Morgan",
      "verb": "adjusts",
      "object": "forecast",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "importance": 33
    },
    {
      "type": "SVO",
      "subject": "Healthcare",
      "verb": "reported",
      "object": "results",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "importance": 33
    },
    {
      "type": "SVO",
      "subject": "Fitzgerald",
      "verb": "cut",
      "object": "estimate",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "importance": 10
    },
    {
      "type": "SVO",
      "subject": "Fitzgerald",
      "verb": "cuts",
      "object": "EPS",
      "sentence": "Cantor Fitzgerald cuts EPS\nNegative Sentiment:",
      "importance": 2
    },
    {
      "type": "SVO",
      "subject": "Stanley",
      "verb": "downgraded",
      "object": "MOH",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "importance": 9
    },
    {
      "type": "SVO",
      "subject": "Stock",
      "verb": "hits",
      "object": "low",
      "sentence": "Stock hits 52-week low\nNegative Sentiment:",
      "importance": 4
    },
    {
      "type": "SVO",
      "subject": "MOH",
      "verb": "faces",
      "object": "challenges",
      "sentence": "Analysts warn MOH faces near-term challenges in its Medicaid plans and may face further downgrades absent clearer margin improvements.",
      "importance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": ",",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "Inc",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "52",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": ",",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "Inc",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "52",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": ",",
      "entity1_type": "ORG",
      "entity2": "Inc",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": ",",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": ",",
      "entity1_type": "ORG",
      "entity2": "52",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": ",",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": ",",
      "entity1_type": "ORG",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc",
      "entity1_type": "ORG",
      "entity2": "52",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc",
      "entity1_type": "ORG",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "52",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "52",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "52",
      "entity1_type": "DATE",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "400",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "330",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "roughly",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "49",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Mizuho",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 51
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 68
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 69
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 77
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 78
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 81
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 82
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 87
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 88
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 89
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "400",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "330",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "roughly",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "49",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Mizuho",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 62
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 63
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 71
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 72
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 75
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 76
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 81
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 82
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 83
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "330",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "roughly",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "49",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "Mizuho",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 59
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 60
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 68
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 69
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 72
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 73
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 78
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 79
    },
    {
      "type": "co-occurrence",
      "entity1": "400",
      "entity1_type": "MONEY",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 80
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "roughly",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "49",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "Mizuho",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 56
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 65
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 66
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 69
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 70
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 75
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 76
    },
    {
      "type": "co-occurrence",
      "entity1": "330",
      "entity1_type": "MONEY",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 77
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "49",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "Mizuho",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 55
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 56
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 59
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 60
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 65
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 66
    },
    {
      "type": "co-occurrence",
      "entity1": "roughly",
      "entity1_type": "PERCENT",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 67
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "Mizuho",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 55
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 59
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 64
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 65
    },
    {
      "type": "co-occurrence",
      "entity1": "49",
      "entity1_type": "PERCENT",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 66
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Mizuho",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 44
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 53
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 63
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 64
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 65
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 50
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 51
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 56
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "Mizuho",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 49
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "333",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "350",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "333",
      "entity1_type": "MONEY",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "350",
      "entity1_type": "MONEY",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "JP",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "JP",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Molina",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "Healthcare",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Molina",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Healthcare",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "2025",
      "entity1_type": "DATE",
      "entity2": "full",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "2025",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "2025",
      "entity1_type": "DATE",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "full",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "full",
      "entity1_type": "DATE",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "July",
      "entity2_type": "DATE",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "11",
      "entity2_type": "DATE",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Medicaid",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "July",
      "entity1_type": "DATE",
      "entity2": "11",
      "entity2_type": "DATE",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "July",
      "entity1_type": "DATE",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "July",
      "entity1_type": "DATE",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "July",
      "entity1_type": "DATE",
      "entity2": "Medicaid",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "11",
      "entity1_type": "DATE",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "11",
      "entity1_type": "DATE",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "11",
      "entity1_type": "DATE",
      "entity2": "Medicaid",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "Medicaid",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Medicaid",
      "entity2_type": "ORG",
      "sentence": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "Cantor",
      "entity2_type": "ORG",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "22.00",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "24.65",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "24.40",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "22.00",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "24.65",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "24.40",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "22.00",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "24.65",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "24.40",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "22.00",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "24.65",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "24.40",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "22.00",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "24.65",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "24.40",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "22.00",
      "entity1_type": "MONEY",
      "entity2": "24.65",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "22.00",
      "entity1_type": "MONEY",
      "entity2": "24.40",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "24.65",
      "entity1_type": "MONEY",
      "entity2": "24.40",
      "entity2_type": "MONEY",
      "sentence": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "Cantor Fitzgerald cuts EPS\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Stanley",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "266",
      "entity2_type": "MONEY",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "364",
      "entity2_type": "MONEY",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Stanley",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "Stanley",
      "entity1_type": "ORG",
      "entity2": "MOH",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Stanley",
      "entity1_type": "ORG",
      "entity2": "266",
      "entity2_type": "MONEY",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "Stanley",
      "entity1_type": "ORG",
      "entity2": "364",
      "entity2_type": "MONEY",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "Stanley",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "Stanley",
      "entity1_type": "ORG",
      "entity2": "Stanley",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "266",
      "entity2_type": "MONEY",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "364",
      "entity2_type": "MONEY",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Stanley",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "266",
      "entity1_type": "MONEY",
      "entity2": "364",
      "entity2_type": "MONEY",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "266",
      "entity1_type": "MONEY",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "266",
      "entity1_type": "MONEY",
      "entity2": "Stanley",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "364",
      "entity1_type": "MONEY",
      "entity2": "Morgan",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "364",
      "entity1_type": "MONEY",
      "entity2": "Stanley",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Morgan",
      "entity1_type": "ORG",
      "entity2": "Stanley",
      "entity2_type": "ORG",
      "sentence": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "52",
      "entity2_type": "DATE",
      "sentence": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "52",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "52",
      "entity1_type": "DATE",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "52",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Stock hits 52-week low\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "52",
      "entity1_type": "DATE",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Stock hits 52-week low\nNegative Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "week",
      "entity2_type": "DATE",
      "sentence": "Stock hits 52-week low\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "MOH",
      "entity1_type": "ORG",
      "entity2": "Medicaid",
      "entity2_type": "ORG",
      "sentence": "Analysts warn MOH faces near-term challenges in its Medicaid plans and may face further downgrades absent clearer margin improvements.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "+",
      "entity2_type": "DATE",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "days",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "days",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "days",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "ago",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "ago",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "AI",
      "entity1_type": "ORG",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "distance": 1
    }
  ],
  "key_phrases": [
    {
      "text": "a string",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "analyst reviews",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "sector headwinds",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "the stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "its 52-week low",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "mixed signals",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "price targets",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "earnings forecasts",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its price target",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "an “outperform” rating",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "roughly 49% upside",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "current levels",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "price target",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "JP Morgan",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its price target",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a Hold rating",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "cautious outlook",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "outright bearishness",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "JP Morgan",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Molina Healthcare",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "preliminary Q2 2025 results",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "updated full-year EPS guidance",
      "type": "noun_chunk",
      "category": "temporal"
    },
    {
      "text": "the official release",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Q2 preliminary results",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "equities analysts",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a range",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "FY2025 earnings forecasts",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "Medicaid managed-care margins",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "FY2025 earnings predictions",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Cantor Fitzgerald",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its FY2025 EPS estimate",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "the consensus",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Cantor Fitzgerald",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Morgan Stanley",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Equal Weight",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its target",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "less confidence",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "near-term upside",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "MOH stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "a 52-week low",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "the earnings estimate revisions",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "broader sector pressures",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "managed care providers",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "52-week low",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "near-term challenges",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its Medicaid plans",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "further downgrades",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "clearer margin improvements",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "$400",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$330",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$333",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$350",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$22.00",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$24.65",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$24.40",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$266",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$364,",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "49%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "Q2 2025",
      "type": "pattern",
      "category": "quarter"
    },
    {
      "text": "FY2025",
      "type": "pattern",
      "category": "fiscal_year"
    },
    {
      "text": "FY2025",
      "type": "pattern",
      "category": "fiscal_year"
    },
    {
      "text": "FY2025",
      "type": "pattern",
      "category": "fiscal_year"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Stock",
      "type": "pattern",
      "category": "market_term"
    }
  ],
  "important_sentences": [
    {
      "text": "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release.",
      "importance_score": 125,
      "entity_count": 22,
      "financial_keyword_count": 11,
      "money_count": 4,
      "company_count": 7,
      "sentiment": "positive"
    },
    {
      "text": "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability.",
      "importance_score": 45,
      "entity_count": 8,
      "financial_keyword_count": 2,
      "money_count": 3,
      "company_count": 2,
      "sentiment": "negative"
    },
    {
      "text": "Morgan Stanley downgraded MOH from “Overweight” to “Equal Weight” and slashed its target to $266 from $364, signaling less confidence in near-term upside.\nMorgan Stanley downgrade\nNegative Sentiment:",
      "importance_score": 42,
      "entity_count": 7,
      "financial_keyword_count": 2,
      "money_count": 2,
      "company_count": 3,
      "sentiment": "negative"
    },
    {
      "text": "Molina Healthcare, Inc (NYSE:MOH) shares have been under pressure following a string of analyst reviews and sector headwinds, pushing the stock toward its 52-week low.",
      "importance_score": 33,
      "entity_count": 8,
      "financial_keyword_count": 3,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "importance_score": 26,
      "entity_count": 6,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Analyst warns of downgrade\nPosted 1+ days ago\nAI Generated.",
      "importance_score": 25,
      "entity_count": 6,
      "financial_keyword_count": 3,
      "money_count": 0,
      "company_count": 1,
      "sentiment": "neutral"
    },
    {
      "text": "MOH stock sank to a 52-week low amid the earnings estimate revisions and broader sector pressures on managed care providers.",
      "importance_score": 24,
      "entity_count": 4,
      "financial_keyword_count": 4,
      "money_count": 0,
      "company_count": 1,
      "sentiment": "neutral"
    },
    {
      "text": "Analysts warn MOH faces near-term challenges in its Medicaid plans and may face further downgrades absent clearer margin improvements.",
      "importance_score": 15,
      "entity_count": 2,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Stock hits 52-week low\nNegative Sentiment:",
      "importance_score": 9,
      "entity_count": 3,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 0,
      "sentiment": "negative"
    },
    {
      "text": "Cantor Fitzgerald cuts EPS\nNegative Sentiment:",
      "importance_score": 8,
      "entity_count": 2,
      "financial_keyword_count": 0,
      "money_count": 0,
      "company_count": 1,
      "sentiment": "negative"
    }
  ],
  "entity_statistics": {
    "total_entities": 42,
    "unique_entities": 26,
    "type_counts": {
      "ORG": 21,
      "DATE": 11,
      "MONEY": 9,
      "PERCENT": 1
    },
    "type_distribution": {
      "ORG": 0.5,
      "DATE": 0.2619047619047619,
      "MONEY": 0.21428571428571427,
      "PERCENT": 0.023809523809523808
    },
    "most_common_entities": [
      [
        "MOH",
        8
      ],
      [
        "52-week",
        3
      ],
      [
        "FY2025",
        3
      ],
      [
        "Mizuho",
        2
      ],
      [
        "JP Morgan",
        2
      ],
      [
        "Medicaid",
        2
      ],
      [
        "Cantor Fitzgerald",
        2
      ],
      [
        "Morgan Stanley",
        2
      ],
      [
        "Molina Healthcare, Inc",
        1
      ],
      [
        "400",
        1
      ]
    ],
    "entity_types_found": [
      "ORG",
      "DATE",
      "MONEY",
      "PERCENT"
    ],
    "company_entities": 21,
    "person_entities": 0,
    "financial_entities": 10,
    "entity_density": 0.16733067729083664
  },
  "financial_analysis": {
    "money_amounts": [
      "400",
      "330",
      "333",
      "350",
      "22.00",
      "24.65",
      "24.40",
      "266",
      "364"
    ],
    "percentages": [
      "roughly 49%"
    ],
    "companies": [
      "Molina Healthcare, Inc",
      "MOH",
      "Mizuho",
      "MOH",
      "Mizuho",
      "JP Morgan",
      "MOH",
      "JP Morgan",
      "Molina Healthcare",
      "MOH",
      "Medicaid",
      "Cantor Fitzgerald",
      "MOH",
      "Cantor Fitzgerald",
      "Morgan Stanley",
      "MOH",
      "Morgan Stanley",
      "MOH",
      "MOH",
      "Medicaid",
      "AI Generated"
    ],
    "people": [],
    "dates": [
      "52-week",
      "Q2 2025",
      "full-year",
      "Q2",
      "July 11",
      "FY2025",
      "FY2025",
      "FY2025",
      "52-week",
      "52-week",
      "1+ days ago"
    ],
    "financial_terms": [
      "earnings",
      "Stock",
      "stock"
    ],
    "financial_metrics": [],
    "market_indicators": [
      "price",
      "rating",
      "target",
      "downgrade"
    ]
  },
  "temporal_analysis": {
    "dates": [
      "52-week",
      "Q2 2025",
      "full-year",
      "Q2",
      "July 11",
      "FY2025",
      "FY2025",
      "FY2025",
      "52-week",
      "52-week",
      "1+ days ago"
    ],
    "time_expressions": [],
    "temporal_relationships": [],
    "quarters": [
      "Q2 2025",
      "Q2"
    ],
    "years": [
      "Q2 2025"
    ],
    "time_periods": []
  },
  "sentiment_analysis": {
    "positive_words": 1,
    "negative_words": 4,
    "positive_ratio": 0.00398406374501992,
    "negative_ratio": 0.01593625498007968,
    "sentiment_score": -0.01195219123505976,
    "sentiment_label": "negative",
    "sentiment_strength": 0.01195219123505976,
    "confidence": 0.11952191235059761
  },
  "industry_analysis": {
    "dominant_industry": "healthcare",
    "industry_scores": {
      "tech": 1,
      "finance": 0,
      "healthcare": 2,
      "energy": 0,
      "retail": 0,
      "automotive": 0,
      "media": 0,
      "industrial": 0,
      "real_estate": 0,
      "telecom": 0,
      "food_beverage": 0,
      "travel": 0,
      "education": 0,
      "professional": 0,
      "mining": 0,
      "aerospace": 0,
      "environmental": 0,
      "cannabis": 0
    },
    "confidence": 0.6666666666666666
  },
  "market_analysis": {
    "market_sentiment": "bearish",
    "bullish_indicators": 0,
    "bearish_indicators": 1,
    "market_conditions": {
      "volatility": "normal",
      "volume": "normal",
      "trend": "bearish"
    },
    "trading_activity": "normal"
  },
  "competitor_analysis": {
    "companies_mentioned": [
      "Molina Healthcare, Inc",
      "MOH",
      "Mizuho",
      "MOH",
      "Mizuho",
      "JP Morgan",
      "MOH",
      "JP Morgan",
      "Molina Healthcare",
      "MOH",
      "Medicaid",
      "Cantor Fitzgerald",
      "MOH",
      "Cantor Fitzgerald",
      "Morgan Stanley",
      "MOH",
      "Morgan Stanley",
      "MOH",
      "MOH",
      "Medicaid",
      "AI Generated"
    ],
    "competitive_context": [
      "Positive Sentiment:\nMizuho lowered its price target on MOH from $400 to $330 but maintained an “outperform” rating, implying roughly 49% upside from current levels.\nMizuho cuts price target\nNeutral Sentiment:\nJP Morgan trimmed its price target to $333 from $350 but left MOH at a Hold rating, reflecting cautious outlook without outright bearishness.\nJP Morgan adjusts forecast\nNeutral Sentiment:\nMolina Healthcare reported preliminary Q2 2025 results and provided updated full-year EPS guidance, with details to be confirmed in the official release."
    ],
    "competitor_count": 21,
    "has_competitive_language": true
  },
  "risk_analysis": {
    "risk_sentences": [
      "Q2 preliminary results\nNeutral Sentiment:\nAround July 11, equities analysts published a range of FY2025 earnings forecasts for MOH, highlighting uncertainty in Medicaid managed-care margins.",
      "FY2025 earnings predictions\nNegative Sentiment:\nCantor Fitzgerald cut its FY2025 EPS estimate for MOH to $22.00 from $24.65, below the consensus of $24.40, reflecting concerns over profitability."
    ],
    "risk_count": 2,
    "risk_level": "medium"
  },
  "opportunity_analysis": {
    "opportunity_sentences": [],
    "opportunity_count": 0,
    "opportunity_level": "low"
  },
  "processing_metadata": {
    "timestamp": "2025-07-13T04:02:35.605867",
    "model_used": "en_core_web_trf",
    "text_length": 1826
  }
}